Related Experiment Video
Updated: Jun 25, 2025
Author Spotlight: Advancing the Analysis of Plasma Extracellular Vesicle Proteome for Cardiovascular Biomarker Studies
Published on: January 31, 2025
Extracellular Vesicles to Predict Outcomes After Transcatheter Aortic Valve Implantation - a Prospective, Multicenter
Radosław Wilimski1, Jan Budzianowski2,3,4, Michał Łomiak5
1Department of Cardiac Surgery, Medical University of Warsaw, Warsaw, Poland.
Transcatheter aortic valve implantation (TAVI) affects plasma extracellular vesicle (EV) concentrations. Pre-TAVI levels of phosphatidylserine-exposing EVs predict major adverse cardiovascular and cerebrovascular events (MACCE) post-procedure.
Area of Science:
- Cardiovascular Medicine
- Nanotechnology
- Biomarkers
Background:
- Transcatheter aortic valve implantation (TAVI) treats aortic stenosis (AS) in high-risk patients.
- Extracellular vesicles (EVs) are nanoparticles implicated in cardiovascular disease pathogenesis.
Purpose of the Study:
- To investigate TAVI's impact on plasma EV subtypes.
- To assess the predictive capability of EVs for post-TAVI outcomes.
Main Methods:
- Plasma samples collected pre-TAVI and at discharge.
- EV concentrations measured using flow cytometry.
Main Results:
- Leukocyte EV concentrations decreased post-TAVI (p=0.008).
- Increased pre-TAVI phosphatidylserine-exposing EVs independently predicted MACCE (OR 5.313, p=0.031).
Conclusions:
- Elevated pre-TAVI procoagulant, phosphatidylserine-exposing EVs are associated with >5-fold increased odds of adverse outcomes.
More Related Videos
09:57Four-Dimensional Computed Tomography-Guided Valve Sizing for Transcatheter Pulmonary Valve Replacement
Published on: January 20, 2022
06:59Improved Registration of 3D CT Angiography with X-ray Fluoroscopy for Image Fusion During Transcatheter Aortic Valve Implantation
Published on: June 3, 2018